VIVOZON Pharmaceutical’s Enafraju Q2 Sales Reach 2 Billion Won... Up 229% from Previous Quarter
Monthly Sales Surpass 1 Billion Won in June for the First Time
Expansion of Supply to Major Hospitals
Additional 120,000 Vials Ordered for Domestic Market
Preparations Underway for Phase 3 Clinical Trials in the US
VIVOZON Pharmaceutical announced on the 18th that the second-quarter sales of its non-narcotic analgesic 'Enafraju' reached approximately 2 billion won, marking a 229% increase compared to the previous quarter.
According to VIVOZON Pharmaceutical, sales of Enafraju rose from about 300 million won in April to 700 million won in May, and 1 billion won in June. In June, monthly sales surpassed 1 billion won for the first time since the product was launched in October of last year.
VIVOZON Pharmaceutical is expanding distribution, focusing on major general hospitals such as Samsung Medical Center and Shinchon Severance Hospital. The company is also widening the prescription base by expanding Drug Committee (DC) reviews to include not only general hospitals but also hospitals with fewer than 300 beds.
With the increase in sales, the company recently placed an additional order for approximately 120,000 vials. Production is being handled by its existing manufacturing partner, Huiyu Pharmaceutical of China.
The company is also promoting global commercialization. Its affiliate, VIVOZON, is expanding patents related to the high-concentration injectable formulation of Enafra, and has recently received a patent registration decision from the Eurasian Patent Office (EAPO). Preparations are underway for a Phase 3 clinical trial in the United States using this formulation, and clinical drug manufacturing for these trials has begun through a global contract manufacturer.
Hot Picks Today
"Earned 500 Million Won in Three Months from Samsung Electronics"... Cash-Rich Samyang Foods' Stock Investment Revealed
- While Retail Investors Suffer, Over 110 Billion Won in Fees Collected Effortlessly... Samsung Electronics and SK hynix ETFs Sweep Up Profits
- "One Billion Won Salary in Just Six Months": Securities Firms on the Verge of Surpassing Banks in Job Preference
- Even With Salaries Exceeding KRW 100 Million, Young Talent Continues to Depart... Rising Concerns Over Mass Resignations at KDB and Eximbank [Public Financial Institution Relocation] ①
- "Has North Korea Imported Maunjaero?" Kim Ju Ae Shows Striking Transformation with Sharper Jawline and Slimmer Face
A representative from VIVOZON Pharmaceutical stated, "As supply is being expanded primarily to major medical institutions, sales in the second quarter more than tripled compared to the previous quarter. We will pursue solidifying our position in the domestic market and advancing global commercialization through securing additional production volume and further expanding supply to medical institutions."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
